About Candel Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.candeltx.com/
Frequently Asked Questions
What is the 52-week range for CADL?
The 52-week high is $14 and the 52-week low is $4.35.
What is the P/E ratio for CADL?
The P/E ratio data is currently unavailable.
What is the dividend yield for CADL?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -89.38%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -15156.45%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.97.
Analyst Recommendation Trends
Wall Street analyst consensus for CADL over the last few months:
Latest CADL News
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on September 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to 4 new employees, stock options to purchase an aggregate of 85,900 shares of the Company’s common stock, with a pe
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI) NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today a
Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC Showing Inadequate Response To ICI.
Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint
CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’
Candel’s experimental therapy combined with radiation therapy improved outcomes in patients with localized prostate cancer
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide mechanistic support for the long-term clinical outcomes, including disease-free survival and prolonged time to biochemical failure, time to metastasis, and time to salvage anti-cancer therapy, observed in this patient populationBiodistribution and shedding data from the PrTK05 phase 2 tria
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
AI-enabled digital pathology analysis shows aglatimagene significantly increased lymphocyte infiltration and immune engagement with tumor cells compared to standard-of-care radiotherapy alone two years after treatment NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the
Candel Therapeutics Announces Immunological Biomarker Data From Ongoing Phase 2 Prtk05 Trial In Patients With Intermediate-Risk Localized Prostate Cancer
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these findings provide
Candel Therapeutics Presents New Biomarker Data From Its Phase 3 Clinical Study Of Aglatimagene Besadenovec
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4
Candel Therapeutics is upgraded to Strong Buy after phase 3 prostate cancer win; 30% lower recurrence supports 2026 BLA. Click for this CADL update.
This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Analysts upgraded MAC, INVH, CIEN, AMH and CADL, raising ratings and several price targets.
B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18
B of A Securities analyst Alec Stranahan upgrades Candel Therapeutics (NASDAQ:CADL) from Neutral to Buy and raises the price target from $12 to $18.
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Martine Zimmermann, PharmD, to the
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Loggia Nicoletta | +380 | $8.676 | $3,297 |
| 2026-09-30 | Manning Paul B | +2,189 | $8.676 | $18,992 |
| 2026-09-30 | PAPA JOSEPH C | +1,325 | $8.676 | $11,496 |
| 2026-09-11 | Tak Paul Peter | -59,379 | $10.4564 | $620,891 |
| 2026-09-10 | Tak Paul Peter | -125,000 | - | - |
| 2026-09-10 | Tak Paul Peter | -220,866 | $11.4997 | $2,539,893 |
| 2026-09-10 | Tak Paul Peter | +125,000 | $1.55 | $193,750 |
| 2026-09-08 | Zimmermann Martine | +64,000 | - | - |
| 2026-08-17 | Tyagarajan Seshu | -7,000 | $12 | $84,000 |
| 2026-07-06 | Sims Mark E. | +285,000 | - | - |
| 2026-06-30 | Loggia Nicoletta | +381 | $8.639 | $3,291 |
| 2026-06-30 | Manning Paul B | +2,199 | $8.639 | $18,997 |
| 2026-06-30 | PAPA JOSEPH C | +1,331 | $8.639 | $11,499 |
| 2026-06-29 | Tyagarajan Seshu | -7,000 | $10.0216 | $70,151 |
| 2026-06-29 | Barone Francesca | -23,447 | $10.0554 | $235,769 |
| 2026-06-23 | Radhakrishnan Maha | +32,000 | - | - |
| 2026-06-23 | Loggia Nicoletta | +32,000 | - | - |
| 2026-06-23 | Martell Christopher | +32,000 | - | - |
| 2026-06-23 | Nabel Gary J. | +32,000 | - | - |
| 2026-06-23 | Nguyen Diem | +32,000 | - | - |
| 2026-06-23 | Gaeta Renee | +32,000 | - | - |
| 2026-06-23 | Benz Edward J. JR | +32,000 | - | - |
| 2026-06-23 | Manning Paul B | +32,000 | - | - |
| 2026-06-23 | PAPA JOSEPH C | +32,000 | - | - |
| 2026-03-31 | Loggia Nicoletta | +779 | $4.114 | $3,205 |
| 2026-03-31 | Manning Paul B | +4,618 | $4.114 | $18,998 |
| 2026-03-31 | PAPA JOSEPH C | +2,795 | $4.114 | $11,499 |
| 2026-02-23 | Manning Paul B | +550,458 | $5.45 | $2,999,996 |
| 2026-01-26 | Tyagarajan Seshu | +154,000 | - | - |
| 2026-01-26 | Schoch Charles | +232,000 | - | - |
| 2026-01-26 | Tak Paul Peter | +629,000 | - | - |
| 2026-01-26 | Barone Francesca | +232,000 | - | - |
| 2026-01-26 | Nichols William Garrett | +136,500 | - | - |